159 related articles for article (PubMed ID: 15179590)
1. [Longterm outcome of TNF blockade in adult-onset Still's disease].
Dechant C; Schauenberg P; Antoni CE; Kraetsch HG; Kalden JR; Manger B
Dtsch Med Wochenschr; 2004 Jun; 129(23):1308-12. PubMed ID: 15179590
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences.
Kraetsch HG; Antoni C; Kalden JR; Manger B
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii55-7. PubMed ID: 11890655
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.
Fautrel B; Sibilia J; Mariette X; Combe B;
Ann Rheum Dis; 2005 Feb; 64(2):262-6. PubMed ID: 15184196
[TBL] [Abstract][Full Text] [Related]
4. Biological treatment in adult-onset Still's disease.
Pouchot J; Arlet JB
Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):477-87. PubMed ID: 23040362
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
6. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
7. Etanercept in the treatment of adult patients with Still's disease.
Husni ME; Maier AL; Mease PJ; Overman SS; Fraser P; Gravallese EM; Weinblatt ME
Arthritis Rheum; 2002 May; 46(5):1171-6. PubMed ID: 12115220
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of biological agents in adult-onset Still's disease.
Cavalli G; Franchini S; Aiello P; Guglielmi B; Berti A; Campochiaro C; Sabbadini MG; Baldissera E; Dagna L
Scand J Rheumatol; 2015; 44(4):309-14. PubMed ID: 25656459
[TBL] [Abstract][Full Text] [Related]
9. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration.
Kaneko K; Kaburaki M; Muraoka S; Tanaka N; Yamamoto T; Kusunoki Y; Abe H; Endo H; Kawai S
Int J Rheum Dis; 2010 Oct; 13(4):e67-9. PubMed ID: 21199457
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders.
Aeberli D; Oertle S; Mauron H; Reichenbach S; Jordi B; Villiger PM
Swiss Med Wkly; 2002 Jul; 132(29-30):414-22. PubMed ID: 12428187
[TBL] [Abstract][Full Text] [Related]
11. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
12. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
[TBL] [Abstract][Full Text] [Related]
13. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report.
Benucci M; Li GF; Del Rosso A; Manfredi M
Clin Exp Rheumatol; 2005; 23(5):733. PubMed ID: 16173267
[No Abstract] [Full Text] [Related]
15. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
16. Adult-onset Still's disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept.
Kuek A; Weerakoon A; Ahmed K; Ostör AJ
Rheumatology (Oxford); 2007 Jun; 46(6):1043-4. PubMed ID: 17449487
[No Abstract] [Full Text] [Related]
17. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
18. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
19. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan.
Suematsu R; Ohta A; Matsuura E; Takahashi H; Fujii T; Horiuchi T; Minota S; Ishigatsubo Y; Ota T; Takei S; Soejima S; Inoue H; Koarada S; Tada Y; Nagasawa K
Mod Rheumatol; 2012 Sep; 22(5):712-9. PubMed ID: 22160845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
